PRME
Prime Medicine, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$637.57M
P/E Ratio
—
EPS
$-1.35
Beta
2.67
52W High
$6.94
52W Low
$1.11
50-Day MA
$3.71
200-Day MA
$4.07
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc. is a forefront biotechnology company innovating in genetic medicine through its proprietary Prime Editing technology, which allows for precise DNA modifications. With a robust pipeline focused on addressing severe diseases, including genetic disorders and various cancers, the company is well-positioned to tackle substantial unmet medical needs. Supported by strong intellectual property assets, Prime Medicine is poised to be a significant contributor to the biopharmaceutical industry, offering promising growth opportunities and transformative solutions that could redefine treatment paradigms.
Fundamentals
| Revenue (TTM) | $4.63M |
| Gross Profit (TTM) | $-156.00M |
| EBITDA | $-201.03M |
| Operating Margin | -5800.00% |
| Return on Equity | -146.80% |
| Return on Assets | -40.70% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.68 |
| Price-to-Book | 5.51 |
| Price-to-Sales (TTM) | 137.65 |
| EV/Revenue | 130.66 |
| EV/EBITDA | -3.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -61.60% |
| Shares Outstanding | $180.62M |
| Float | $105.20M |
| % Insiders | 23.76% |
| % Institutions | 64.59% |
Historical Volatility
HV 10-Day
49.28%
HV 20-Day
48.41%
HV 30-Day
63.01%
HV 60-Day
72.24%
HV Rank
3.6%
Volatility is currently contracting
Analyst Ratings
Consensus ($6.92 target)
1
Strong Buy8
Buy4
HoldData last updated: 4/30/2026